<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201197</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00207237</org_study_id>
    <secondary_id>U54AT008909</secondary_id>
    <nct_id>NCT04201197</nct_id>
  </id_info>
  <brief_title>Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs</brief_title>
  <official_title>Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate drug-drug interactions between cannabis extracts containing&#xD;
      Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450&#xD;
      pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9),&#xD;
      dextromethorphan (CYP2D6), and midazolam (CYP3A).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the widespread use and availability of cannabis products, substantive deficiencies&#xD;
      remain regarding the potential risks for cannabis or cannabinoids to precipitate adverse&#xD;
      interactions with conventional drugs. Evidence from the few systematic clinical studies that&#xD;
      have been conducted suggests that THC and CBD can inhibit metabolism of other drugs, via&#xD;
      interactions with cytochrome P450 (CYP) enzymes, a large family of enzymes involved in the&#xD;
      metabolism of numerous drugs and foreign chemicals in the body. Accordingly, evaluating the&#xD;
      potential for drug-drug interactions between cannabis-derived products and common&#xD;
      CYP-metabolized drugs merits further investigation. This double-blind, randomized crossover&#xD;
      design study will evaluate whether, and to what extent, oral administration of cannabis&#xD;
      extracts containing high doses of CBD and/or THC alter the pharmacokinetics of 5 drugs&#xD;
      metabolized via CYP pathways including: caffeine (CYP1A2), omeprazole (CYP2C19), losartan&#xD;
      (CYP2C9), dextromethorphan (CYP2D6), and midazolam (CYP3A). Healthy adults will complete&#xD;
      three experimental dosing sessions, in which participants will orally ingest brownies&#xD;
      containing (1) a high THC cannabis extract with a target THC dose of 40mg, (2) a high CBD&#xD;
      cannabis extract with a target CBD dose of 1350mg + a THC dose of 40mg, or (3) placebo. In&#xD;
      all three experimental dosing sessions, consumption of the cannabis extract infused brownie&#xD;
      will be followed by ingestion of a drug &quot;cocktail&quot; comprised of commercial formulations of&#xD;
      therapeutic or subtherapeutic doses of each drug. This collection of probe drugs, coined the&#xD;
      Inje Cocktail, has been demonstrated to be safe, both administered alone and with various&#xD;
      CYP450 inhibitors. At baseline and following administration of the study drugs, a battery of&#xD;
      subjective, physiological, and cognitive performance assessments will be completed and&#xD;
      biological specimens obtained. Each session will consist of a 12-hour outpatient drug&#xD;
      administration visit and a 1-hour outpatient visit the subsequent day for additional&#xD;
      biospecimen collection, cognitive testing, and subjective drug effect questionnaires. The&#xD;
      study will conclude when 18 participants complete all 3 experimental sessions. The outcomes&#xD;
      of this study will be useful to inform clinical decision-making regarding co-administration&#xD;
      of cannabinoid-containing products with drugs that are either commonly prescribed by&#xD;
      physicians or readily available over-the-counter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Placebo controlled, double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Losartan Area Under the Curve (AUC) in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve concentration (mg/mL) of losartan in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caffeine AUC in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve concentration (mg/mL) of caffeine in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Omeprazole AUC in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve concentration (mg/mL) of omeprazole in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dextromethorphan AUC in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve concentration (mg/mL) of dextromethorphan in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Midazolam AUC in plasma</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve concentration (mg/mL) of midazolam in plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Drug-Interactions</condition>
  <arm_group>
    <arm_group_label>Inje Cocktail</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inje Cocktail + THC extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inje Cocktail + THC/CBD extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC and 1350mg CBD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inje cocktail</intervention_name>
    <description>Acute drug exposure</description>
    <arm_group_label>Inje Cocktail</arm_group_label>
    <arm_group_label>Inje Cocktail + THC extract</arm_group_label>
    <arm_group_label>Inje Cocktail + THC/CBD extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC Cannabis extract</intervention_name>
    <description>Acute drug exposure</description>
    <arm_group_label>Inje Cocktail + THC extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC/CBD Cannabis Extract</intervention_name>
    <description>Acute drug exposure</description>
    <arm_group_label>Inje Cocktail + THC/CBD extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult between 18-50 years old&#xD;
&#xD;
          -  BMI between 18 to 34 kg/m2&#xD;
&#xD;
          -  Willing to use birth control&#xD;
&#xD;
          -  Willing to abstain from all medications and citrus fruits for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or psychiatric illness judged by the investigator to put the participant at&#xD;
             greater risk of experiencing an adverse event due to drug exposure or completion of&#xD;
             other study procedures.&#xD;
&#xD;
          -  Use of medications which, in the opinion of the investigator or medical staff, will&#xD;
             interfere with the study outcomes or the safety of the participant.&#xD;
&#xD;
          -  Clinically significant impairment of kidney, liver, or thyroid function (serum&#xD;
             creatinine &gt;1.2 mg/ml (kidney), liver function tests &gt;3x the upper limit of normal&#xD;
             (alanine amino transferase &gt;99 U/L; aspartate amino transferase &gt; 99 U/L), and thyroid&#xD;
             stimulating hormone &gt; 4.2 uIU/ml), or evidence of current anemia based on blood&#xD;
             chemistry testing.&#xD;
&#xD;
          -  History of adverse events associated with the ingestion of cannabis or any medications&#xD;
             in the Inje cocktail judged by the investigator to present an undue risk of harm to&#xD;
             the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Vandrey, PhD</last_name>
    <phone>410-550-4036</phone>
    <email>rvandrey@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Vandrey</last_name>
      <email>rvandrey@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data sharing will be decided on a case by case basis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

